Inventor · disambiguated record
Joseph Robert Pinchman
Also filed as: PINCHMAN JOSEPH ROBERT
26 granted patents·23 pending applications·22 citations·filing 2015–2024
94Inventor score
Files withRECURIUM IP HOLDINGS LLC32XINTHERA INC8ZENO ROYALTIES & MILESTONES LLC5KALYRA PHARMACEUTICALS INC3ZENO MAN INC1
Top patents by PatentIndex Score
49 records- 0196US11813260B1Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2023·Granted Nov 14, 2023·1 cites·20 claims
- 0296US11795173B1Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Oct 24, 2023·5 cites·18 claims
- 0395US12006322B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Jun 11, 2024·2 cites·4 claims
- 0493US11939329B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Mar 26, 2024·2 cites·5 claims
- 0593US11813259B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2022·Granted Nov 14, 2023·1 cites·17 claims
- 0689US2024180899A1Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2023·Application pending·0 cites
- 0787US11590126B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Feb 28, 2023·1 cites·97 claims
- 0887US11344546B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted May 31, 2022·1 cites·109 claims
- 0985US12421241B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2024·Granted Sep 23, 2025·0 cites·4 claims
- 1083US11065234B2Estrogen receptor modulatorsRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Jul 20, 2021·1 cites·32 claims
- 1182US11098030B2EGFR inhibitor compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Aug 24, 2021·1 cites·13 claims
- 1282US10525036B2Spirocyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2016·Granted Jan 7, 2020·2 cites·23 claims
- 1379US12384780B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2024·Granted Aug 12, 2025·0 cites·2 claims
- 1477US10513509B2EGFR inhibitor compoundsKALYRA PHARMACEUTICALS INC·Filed 2017·Granted Dec 24, 2019·1 cites·24 claims
- 1576US10793504B2Methods for cross couplingRECURIUM IP HOLDINGS LLC·Filed 2017·Granted Oct 6, 2020·1 cites·22 claims
- 1675US10308609B2Bicyclic compoundsKALYRA PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·2 cites·22 claims
- 1774US11318134B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted May 3, 2022·0 cites·82 claims
- 1873US12049460B2EGFR inhibitor compoundsRECURIUM IP HOLDINGS LLC·Filed 2021·Granted Jul 30, 2024·0 cites·20 claims
- 1973US2021330651A1Estrogen receptor modulatorsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 2072US10959989B2Estrogen receptor modulatorsRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Mar 30, 2021·0 cites·3 claims
- 2171US10975035B2Bicyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Apr 13, 2021·0 cites·25 claims
- 2271US10493060B2Spirocyclic compoundsZENO ROYALTIES & MILESTONES LLC·Filed 2019·Granted Dec 3, 2019·1 cites·11 claims
- 2370US11065233B2Estrogen receptor modulatorsRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Jul 20, 2021·0 cites·24 claims
- 2469USRE50643EBenzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Oct 21, 2025·0 cites·100 claims
- 2568US2023128041A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Application pending·0 cites
- 2666US11724971B2Process for making [1.1.1]propellaneRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Aug 15, 2023·0 cites·21 claims
- 2765US2024279214A1Alpha4 beta7 inegrin antagonists and uses thereofXINTHERA INC·Filed 2023·Application pending·0 cites
- 2863US2020268714A1Spirocyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2962US2025171418A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Application pending·0 cites
- 3056US2019142811A1Estrogen receptor modulatorsZENO ROYALTIES & MILESTONES LLC·Filed 2017·Application pending·0 cites
- 3156US2023167105A1Bcl-2 protein inhibitorsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3256US2023381172A1Combinations of bcl-2 inhibitors with chemotherapeutic agentsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3354US10653681B2Analgesic compoundsRECURIUM IP HOLDINGS LLC·Filed 2017·Granted May 19, 2020·0 cites·12 claims
- 3454US2023159416A1Difluoromethyl iodo compounds and methodsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3554US2023158048A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3653US11339103B2Continuous flow processes for making bicyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2018·Granted May 24, 2022·0 cites·31 claims
- 3753US2023065577A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 3853US2023212118A1Preparation of an selective estrogen receptor degraderRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3952US2022265834A1Bcl-2 protein inhibitorsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 4052US2023054854A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 4151US2023210846A1Treatment for amyloidosisZENO MAN INC·Filed 2021·Application pending·0 cites
- 4251US2023054767A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 4351US2023008362A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 4449US2022273666A1Nanoparticle formulation of bcl-2 inhibitorRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 4546US11242327B2Analgesic compoundsRECURIUM IP HOLDINGS LLC·Filed 2018·Granted Feb 8, 2022·0 cites·23 claims
- 4639US2019083460A1Analgesic compoundsZENO ROYALTIES & MILESTONES LLC·Filed 2017·Application pending·0 cites
- 4739US2019060257A1Analgesic compoundsZENO ROYALTIES & MILESTONES LLC·Filed 2017·Application pending·0 cites
- 4839US2019099404A1Analgesic compoundsZENO ROYALTIES & MILESTONES LLC·Filed 2017·Application pending·0 cites
- 4936US2018201614A1Bicyclic compoundsKALYRA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joseph Robert Pinchman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →